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Abstract
Background: Chronic insomnia affects up to 63% of family dementia caregivers. Research suggests that chronic insomnia
prompts changes in central stress processing that have downstream negative effects on health and mood, as well as on cognitive,
inflammatory, and neurodegenerative functioning. We hypothesize that cognitive behavioral therapy for insomnia (CBT-I) will
reverse those downstream effects by improving insomnia and restoring healthy central stress processing. Rural caregivers are
particularly vulnerable, but they have limited access to CBT-I; therefore, we developed an accessible digital version using
community input (NiteCAPP CARES).
Objective: This trial will evaluate the acceptability, feasibility, and short-term and long-term effects of NiteCAPP CARES on
the sleep and stress mechanisms underlying poor caregiver health and functioning.
Methods: Dyads (n=100) consisting of caregivers with chronic insomnia and their coresiding persons with dementia will be
recruited from Columbia and surrounding areas in Missouri, United States. Participant dyads will be randomized to 4 weeks (plus
4 bimonthly booster sessions) of NiteCAPP CARES or a web-based sleep hygiene control (NiteCAPP SHARES). Participants
will be assessed at baseline, after treatment, and 6- and 12-month follow-ups. The following assessments will be completed by
caregivers: 1 week of actigraphy and daily diaries measuring sleep, Insomnia Severity Index, arousal (heart rate variability),
inflammation (blood-derived biomarkers: interleukin-6 and C-reactive protein), neurodegeneration (blood-derived biomarkers:
plasma amyloid beta [Aβ40 and Aβ42], total tau, and phosphorylated tau [p-tau181 and p-tau217]), cognition (Joggle battery,
NIH Toolbox for Assessment of Neurological and Behavioral Function, and Cognitive Failures Questionnaire), stress and burden,
health, and mood (depression and anxiety). Persons with dementia will complete 1 week of actigraphy at each time point.
Results: Recruitment procedures started in February 2022. All data are expected to be collected by 2026. Full trial results are
planned to be published by 2027. Secondary analyses of baseline data will be subsequently published.
Conclusions: This randomized controlled trial tests NiteCAPP CARES, a web-based CBT-I for rural caregivers. The knowledge
obtained will address not only what outcomes improve but also how and why they improve and for how long, which will help us
to modify NiteCAPP CARES to optimize treatment potency and support future pragmatic testing and dissemination.
Trial Registration: ClinicalTrials.gov NCT04896775; https://clinicaltrials.gov/ct2/show/NCT04896775
https://www.researchprotocols.org/2022/6/e37874
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Introduction
Background
Approximately 16 million Americans serve as unpaid informal
caregivers (CGs), providing 18.6 billion hours of care, which
translates into US $244 billion in health care savings [1]. The
number of persons with dementia in the United States is
projected to rise from 5.7 million to >14 million in the next 30
years, and most persons with dementia (70%) are cared for at
home by a family member [1]. This rise in the number of persons
with dementia is likely to increase the number of CGs, especially
in rural areas, where populations are aging faster than those in
urban areas [2]. Chronic insomnia (≥3 months difficulty
initiating and maintaining sleep, early morning awakening, or
nonrestorative sleep) affects up to 63% of CGs [3,4] and tends
to endure (18 years on average in our CG studies) [4,5]. Factors
associated with CG insomnia include changes in central stress
processing (increased sympathetic nervous system arousal) [3,6]
as well as worse health and daytime functioning (increased
depression, stress, and cognitive dysfunction). Research [3-5]
shows that cognitive behavioral therapy for insomnia (CBT-I)
is an efficacious treatment for the chronic and particularly
long-lasting insomnia experienced by CGs and suggests that it
may restore healthy central stress processing [7]. However, rural
CGs have less access to care, including CBT-I, because of
significant shortages of both primary and specialty care
providers in rural areas [8]. Web-based CBT-I will allow for
greater dissemination, particularly for rural CGs and persons
with dementia who may have challenges receiving treatment
because of trained provider scarcity [9] and the burden
associated with traditional in-office delivery.
It has been shown by our team as well as another group of
researchers that in-person brief CBT-I (bCBT-I) improves CG
sleep and mood (small to large effects) [10-12]. Early research
by McCurry et al [12] found that in-person bCBT-I improved
CG sleep (efficiency and quality) and depression immediately
and 3 months after treatment compared with a waitlist. Our team
also found that in-person bCBT-I improved sleep, depression,
and anxiety in older adult CGs of persons with dementia [10].
McCrae et al [11] also found that bCBT-I (2 in-person sessions
and 2 telehealth sessions) improved sleep in rural older adults
for at least 3 months compared with the sleep hygiene control.
Our new pilot data also suggest that CBT-I translates well to
telehealth [7,13]. However, telehealth delivery still requires
considerable time commitment from trained therapists (already
in short supply). Thus, web delivery represents an important,
logical next step that would maximize therapist time (ie,
web-based moderation and feedback vs 1 hour per week
one-on-one sessions), reduce CG travel burden, and give both
therapist and CG scheduling flexibility. Web delivery would
also enhance disseminability because the majority of Americans
https://www.researchprotocols.org/2022/6/e37874
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(including rural and older Americans) use the internet and have
access to it [14]. Moreover, several meta-analyses of web-based
CBT-I have indicated moderate to large effect sizes for sleep
improvement that are comparable to in-person CBT-I effects
[15,16]. Although web-based CBT-I has not been tested in CGs,
web interventions have successfully improved noninsomnia
health outcomes in stroke and CGs [7,17]. These findings
provide support for the development and evaluation of
web-based CBT-I for CGs (NiteCAPP CARES) in the proposed
study.
Several considerations were taken into account in the
development of NiteCAPP CARES. For instance, given prior
work showing that providing CGs with behavioral sleep
instructions for their persons with dementia led to improved
sleep in persons with dementia (measured using actigraphy)
[7], NiteCAPP CARES uses a dyadic approach that targets sleep
for both the CG and care recipient. In addition, following
recommendations from other CBT-I studies [16], NiteCAPP
CARES uses a guided therapy approach with trained therapy
moderators monitoring the progress of CGs and persons with
dementia, providing feedback, and answering questions. Taking
a dyadic, guided therapy approach may optimize the impact of
CBT-I on CG mechanisms and outcomes.
Research suggests that CG chronic insomnia results in changes
in central stress processing that have downstream negative
effects on health and daytime functioning. CGs experience
increased subjective stress and arousal because they witness the
distress experienced by persons with dementia and because of
the physical and time demands of caregiving [4,5]. Research
shows that persons with chronic insomnia have alterations in
heart rate (HR) and HR variability (HRV) while awake before
sleep and during stage 2 non–rapid eye movement sleep [18],
as well as lower wake-to-sleep HR reduction and SD of
normal-to-normal heartbeat intervals compared with controls
[19], consistent with disrupted autonomic nervous system (ANS)
functioning (increased sympathetic activity). In CGs, increased
self-reported stress is associated with altered HRV during the
first half of sleep (lower high-frequency power values),
indicative of impaired ANS functioning [19]. Our preliminary
results have shown that HRV can be altered because bCBT-I
increased resting HRV in adults with comorbid insomnia [10].
Collectively, the findings in comorbid insomnia and our
preliminary data suggest that physiological arousal serves as a
mechanism underlying other CG symptoms.
CGs also face mental and physical health–related challenges
regarding mood and cognition, as well as neurodegenerative
and inflammatory biomarkers. Sleep may play a role in CGs’
high levels of anxiety and depression [20] because our research
shows that nights of poor sleep (ie, higher total wake time and
poorer sleep quality) were associated with greater next-day
negative affect in CGs [10]. Research, including ours, shows
JMIR Res Protoc 2022 | vol. 11 | iss. 6 | e37874 | p. 2
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that CBT-I can improve depression in CGs [12,21,22]. In
addition, CGs perform worse on tests of processing speed
[23,24], attention [23,25,26], executive function [26], and
memory [26,27] than same age non-CGs. Our recent trial shows
that telehealth CBT-I can improve CG executive functioning
and processing speed [10]. Moreover, preclinical studies link
poor sleep to increased Alzheimer disease–related biomarkers
(plasma amyloid beta [Aβ] and tau), suggesting that sleep is
essential for protein clearance and reduction of neuronal
aggregations contributing to plaques and tangles (hallmark
pathology of Alzheimer disease) [27]. Risk of developing
Alzheimer disease is elevated in CGs versus non-CGs (up to 6
times greater) [28], and CGs have increased peripheral
inflammatory biomarker levels (eg, C-reactive protein) [29].
Sleep quality improvements are associated with reductions in
inflammatory markers associated with Alzheimer disease, that
is, C-reactive protein (small effects) and interleukin-6
concentrations (large effects) [29], as well as expression of
inflammatory-related genes [30]. These studies suggest that
targeting poor sleep may lower Alzheimer disease–related
biomarker levels, thereby mitigating risk and delaying disease
progression. The proposed trial will examine whether treating
CGs’ sleep disturbances through NiteCAPP CARES may help
mitigate their neurodegenerative risks.

McCrae et al
The Cognitive Activation Theory of Stress [31] underlies the
basic premise guiding the proposed trial, namely that CGs
experience chronic insomnia, arousal, and inflammation that
are associated with central nervous system changes that
negatively affect other CG health outcomes (Figure 1).
Specifically, arousal, poor sleep, and inflammation lead to
critical changes in the hypothalamic-pituitary-adrenal axis and
ANS, primarily sympathetic activation functioning, that
contribute to lower health-related quality of life, increased
depression and burden, and decreased cognitive functioning.
We propose that NiteCAPP CARES holds promise for
improving multiple CG health outcomes by improving common
underlying mechanisms (sleep and arousal), thereby restoring
healthy hypothalamic-pituitary-adrenal axis and ANS
functioning. NiteCAPP CARES will engage these mechanisms
using established sleep techniques (sleep education, sleep
hygiene, and stimulus control), modified techniques (for older
adults and CGs; sleep compression and brief relaxation),
techniques for other CG issues (problem solving and stress
management), and by targeting sleep change in persons with
dementia (direct participation of persons with dementia or CG
administration of behavioral techniques).

Figure 1. Conceptual model. Aim 1 (not shown) examines feasibility and acceptability of NiteCAPP CARES and NiteCAPP SHARES. Sleep change
in person with dementia will be examined as an outcome (aim 4) and a potential moderator (exploratory aim: dashed lines) of the relationship between
changes in caregiver (CG) primary and secondary outcomes. Refer to the Outcomes section for a list of potential mediators (eg, adherence) and moderators
(eg, sleep change in person with dementia, interpersonal processes, and shared lifestyle factors). Biomarkers of neurodegeneration and inflammation
will be examined as exploratory CG secondary outcomes (dotted box outline). NiteCAPP CARES: cognitive behavioral therapy for insomnia; NiteCAPP
SHARES: active web-based sleep hygiene and related education control.

The base NiteCAPP platform was developed in 2019 by the
study team and was based on a 4-session CBT-I treatment
protocol developed by the first author (CSM) and used for
research [10,32] and clinical service delivery for >20 years.
Initial adaptations for CGs to create NiteCAPP CARES were
made following the Medical Research Council recommendations
for evaluating complex medical interventions, including
community participation, usability testing, and validation. The
details of the preliminary work are available elsewhere [7].
https://www.researchprotocols.org/2022/6/e37874
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Although the findings from these usability studies were
promising and demonstrated the preliminary feasibility and
acceptability of NiteCAPP CARES as well as its efficacy for
improving sleep and other variables for CGs, they warrant
further investigation in a larger sample and comparison with an
active control condition across a wider range of outcomes. The
proposed trial offers the following methodological
improvements: inclusion of an active control group (web-based
sleep hygiene and related education [NiteCAPP SHARES]),
JMIR Res Protoc 2022 | vol. 11 | iss. 6 | e37874 | p. 3
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increased number and length of follow-ups, and a dyadic
approach (because persons with dementia experience poor sleep
and nighttime behavior that negatively affects CGs). In sum,
the proposed trial addresses significant gaps in the literature
and the need for effective insomnia treatment for CGs and
persons with dementia.

Objectives
The overarching goal of this randomized controlled trial (RCT)
is to evaluate the acceptability, feasibility, and short-term and
long-term effects of NiteCAPP CARES on the sleep and stress
mechanisms underlying poor CG health and functioning. Our
first specific aim is to examine the feasibility and acceptability
of NiteCAPP CARES and an active web control (sleep hygiene
and related education [NiteCAPP SHARES]). We hypothesize
that NiteCAPP CARES and NiteCAPP SHARES will have high
rates of completion (≥75% of sessions), adherence (≥75% of
the techniques implemented), satisfaction (≥7.5 out of 10 on
the Satisfaction Survey), and utility (≥3.5 out of 5 on the Internet
Intervention Utility Questionnaire).
Our second specific aim is to examine the effects of NiteCAPP
CARES on the primary (mechanistic) CG outcomes in our
theory-driven conceptual model; that is, to examine the effects
of 4 weeks of CBT-I compared with 4 weeks of NiteCAPP
SHARES on CG sleep (insomnia severity and self-reported
sleep onset latency, wake time after sleep onset, and sleep
efficiency) and arousal immediately after treatment and at 6and 12-month follow-ups. We hypothesize that compared with
NiteCAPP SHARES, NiteCAPP CARES will improve CG sleep
and decrease arousal.
Our third specific aim is to examine the effects of NiteCAPP
CARES on the secondary CG outcomes in our theory-driven
conceptual model; that is, to examine the effects of 4 weeks of
CBT-I compared with weeks of NiteCAPP SHARES on CG
health, mood, burden, cognition, inflammation, and
neurodegeneration immediately after treatment and at 6- and
12-month follow-ups. We hypothesize that compared with
NiteCAPP SHARES, NiteCAPP CARES will improve these
CG outcomes.
Our fourth specific aim is to test the effect of NiteCAPP CARES
on persons with dementia, the secondary outcome in our
theory-driven conceptual model; that is, to examine the effects
of 4 weeks of CBT-I compared with 4 weeks of NiteCAPP
SHARES on sleep change in persons with dementia (objective
measurement through actigraphy and total sleep time)
immediately after treatment and at 6- and 12-month follow-ups.
We hypothesize that compared with NiteCAPP SHARES,
NiteCAPP CARES will improve sleep in persons with dementia.
Our exploratory aim is to examine the relationships between
CG primary and secondary outcome changes and their potential
mediators (eg, adherence) and moderators (eg, sleep change in
persons with dementia, interpersonal processes, and shared
lifestyle factors).

https://www.researchprotocols.org/2022/6/e37874
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Methods
Trial Design and Study Setting
Dyads (n=100) consisting of CGs with chronic insomnia and
their coresiding persons with dementia will be recruited from
Columbia and surrounding areas in Missouri, United States,
and randomized to 4 sessions of NiteCAPP CARES or
NiteCAPP SHARES. The groups will receive bimonthly
boosters. Baseline and posttreatment assessments as well as
6-month and 12-month follow-ups will measure sleep, arousal,
biomarkers of inflammation and neurodegeneration, health,
mood, burden, and cognition.
Graduate therapists and assessors will obtain written informed
consent from CGs and persons with dementia, if possible. If the
person with dementia is unable to consent (determined by
consultation with the first author [CSM]), a legally authorized
representative must sign a consent form on their behalf. If the
person with dementia becomes unable to provide consent during
the course of the study, the legally authorized representative
will be asked to reconsent on behalf of the care recipient. Dyads
in both groups will receive US $125 at baseline, US $150 after
treatment, US $175 at 6-month follow-up, and US $200 at
12-month follow-up, as well as treatment at no cost. NiteCAPP
SHARES participants will be offered NiteCAPP CARES at no
cost after the study.

Eligibility Criteria
The CG inclusion criteria are as follows: (1) aged ≥18 years,
(2) CG living with persons with dementia, (3) willing to be
randomized, (4) able to read and understand English, (5)
diagnosed with insomnia [33-35], and (6) no newly prescribed
or over-the-counter sleep medications for ≥1 month or stabilized
for ≥6 months. Insomnia diagnosis requires (1) sleep complaints
for ≥6 months, (2) adequate opportunity and circumstances for
sleep, (3) at least one of the following: difficulty falling asleep
or staying asleep or waking too early, (4) daytime dysfunction
(mood, cognitive, social, or occupational) because of insomnia,
and (5) baseline diaries indicate >30 minutes of sleep onset
latency or wake after sleep onset on ≥3 nights.
The CG exclusion criteria are as follows: (1) unable to consent,
(2) cognitive impairment (based on score of ≤25 on the Montreal
Cognitive Assessment), (3) sleep disorder other than insomnia
(ie, apnea (Apnea-Hypopnea Index score>15), (4) bipolar or
seizure disorder, (5) other major psychopathology except
depression or anxiety (eg, suicidal or psychotic), (6) severe
untreated psychiatric comorbidity, (7) psychotropic or other
medications (eg, clonidine) that alter sleep, and (8)
nonpharmacological treatment for sleep or mood outside of
current trial.
The inclusion criteria for persons with dementia are as follows:
(1) probable or possible Alzheimer disease (self-report or
primary care physician’s written confirmation), (2) at least one
problem on the Nighttime Behavior Inventory ≥3 nights per
week, (3) able to tolerate actigraphy, (4) not taking any new
sleep medications for ≥1 month or stabilized ≥6 months, (5)
untreated sleep disorder for which CBT-I is not recommended
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(ie, sleep apnea), and (6) scoring <32 on the sleep apnea scale
on the Sleep Disorders Questionnaire.

Randomization and Blinding
Computer randomization will be performed by the team’s
biostatistician, using a permuted block randomization technique
stratified by baseline sleep medication use (yes or no) [36].
Other personnel (except for therapists, supervisor, and project
coordinator) will be blinded to randomization.

Procedures
Screening
A sleep psychologist (principal investigator CSM) will diagnose
insomnia and make referrals for other suspected sleep disorders
(eg, apnea). Screening will be carried out in four stages:
•

•

•

•

Stage 1: brief screener (15 minutes). The project coordinator
will (1) conduct a brief structured interview to address the
inclusion and exclusion criteria and establish a probable
insomnia diagnosis and (2) administer the Montreal
Cognitive Assessment (CG must score >25, a cutoff chosen
to maintain consistency with our prior clinical trial).
Stage 2: clinical interview (50 minutes). The assessor will
(1) conduct a semistructured sleep and psychiatric interview
and (2) facilitate and assist with web-based baseline
questionnaire completion.
Stage 3: apnea testing (1 overnight session). This consists
of 1 night of at-home sleep testing using disposable
WatchPAT One devices (Itamar Medical Ltd) to rule out
sleep disorders other than insomnia (ie, apnea). The assessor
will instruct CGs on how to use WatchPAT One devices
in their own homes so that the CGs can sleep in their own
beds. Referrals will be made for those disqualified. The
WatchPAT One (a wrist-worn device with 2 finger sensors)
measures peripheral arterial tone, oximetry, actigraphy,
HR, body position, and snoring.
Stage 4: sleep diary confirmation of insomnia (5 minutes
per day). Electronic baseline diaries will confirm insomnia

McCrae et al
diagnosis and must show >30 minutes of sleep onset latency
or wake after sleep onset on ≥3 nights over 7 days. Diaries
will be collected electronically through Qualtrics software
with personal web-enabled devices or (if needed)
study-provided devices and internet service.

Interventions
Both arms (NiteCAPP CARES and NiteCAPP SHARES)
include 4 web-based sessions and 4 bimonthly, 20-minute
boosters (Figure 2) with a therapist moderator (predoctoral
graduate students in an American Psychological
Association–accredited psychology program at the University
of Missouri). Details of the development of NiteCAPP have
been published and are available [7]. Each session is completed
individually by CGs (with persons with dementia to the extent
able) in a single sitting (<45 minutes). Each session should be
completed in 7 days, with the next session released only after
the previous one is completed. All procedures will be conducted
at participants’ homes. Session content details for NiteCAPP
CARES and NiteCAPP SHARES are provided in Textboxes 1
and 2, respectively.
Both interventions will be dyadic, and CGs will work with
persons with dementia to implement behavioral strategies similar
to those used by McCrae et al [10] and McCurry et al [12].
Active participation of persons with dementia is a goal but may
be limited because of dementia symptoms. Behavioral strategies
for persons with dementia will be tailored based on baseline
assessment (use of actigraphy in persons with dementia,
nighttime behaviors, and dementia severity and other
questionnaires). To provide a guided therapy approach, trained
moderators (psychology doctoral students) will (1) monitor
adherence and progress (log-in details and log completion), (2)
provide weekly email feedback on sleep patterns and progress,
(3) answer questions within 24 hours through a web-embedded
message forum, and (4) provide bimonthly boosters (discuss
maintenance and troubleshoot problems).

Figure 2. Session and booster timeline. The randomization numbers refer to dyads (ie, caregivers and their coresiding persons with dementia). B:
booster session; F6: 6-month follow-up; F12: 12-month follow-up; NiteCAPP CARES: cognitive behavioral therapy for insomnia; NiteCAPP SHARES:
active web-based sleep hygiene and related education control.
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Textbox 1. Session content for NiteCAPP CARES.
1. Sleep hygiene, sleep education, and stimulus control
•

Sleep hygiene will be taught, and participants are instructed to adhere to the following rules (the goal of sleep hygiene is to eliminate sleep-interfering
behaviors):
•

avoid caffeine after noon

•

within 2 hours of going to bed, avoid exercise and heavy meals

•

within 1 hour of bedtime, avoid screen time

•

use the bed for sleeping only

2. Sleep compression, relaxation, and problem solving
•

The therapist moderator and caregiver and person with dementia will work together to create a sleep prescription and set regular bed and wake
times consistent with the prescription. Caregiver and person with dementia will be instructed to practice relaxation techniques. Caregiver will
be provided suggestions on how to solve the challenges associated with caregiving for a person with dementia.

3. Coping and stress management and cognitive therapy
•

Sleep prescription for caregiver and person with dementia will be updated as appropriate. Coping and stress management techniques will be
taught. Caregiver and person with dementia will be taught how to identify maladaptive thoughts and replace them with balanced thoughts.

4. Review and education and plan for maintenance of behavior change
•

Sleep prescription for caregiver and person with dementia will be updated as appropriate. Caregiver and person with dementia will be provided
information on how to maintain sleep changes.

5. Booster sessions
•

In this brief (approximately 20 minutes) telephone session, techniques from sessions 1 to 4 will be reviewed. The therapist moderator will
encourage continued practice of techniques and assist in troubleshooting of problems.

Textbox 2. Session content for NiteCAPP SHARES.
1. Expanded sleep education and sleep hygiene
•

Participants are provided sleep education regarding sleep and the brain, mood, behavior, health, and weight. Sleep hygiene will be taught and
participants are instructed to adhere to the following rules (the goal of sleep hygiene is to eliminate sleep-interfering behaviors):
•

avoid caffeine after noon

•

within 2 hours of going to bed, avoid exercise and heavy meals

•

within 1 hour of bedtime, avoid screen time

•

use the bed for sleeping only

2. Insomnia education and sleep hygiene support
•

Participants are provided education on sleep stages and cycles, sleep disorders, and safety precautions regarding sleep.

3. Targeted sleep education and sleep in dementia
•

Participants are provided targeted sleep education and education about sleep in dementia.

4. Review and education and plan for maintenance of behavior change
•

Sleep prescription for caregiver and person with dementia will be updated as appropriate. Caregiver and person with dementia will be provided
information on how to maintain sleep changes.

5. Booster sessions
•

In this brief (approximately 20 minutes) telephone session, techniques from sessions 1 to 4 will be reviewed. The therapist moderator will
encourage continued practice of techniques and assist in troubleshooting of problems.
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Treatment Integrity
The 3-step method formulated by Lichstein [37] will be used
to measure treatment integrity.
Step 1: Treatment Delivery and Training
Moderators use web-based manuals. Practice begins with mock
web-based sessions (ie, moderator and patient interactions),
followed by web-based sessions with volunteers. The principal
investigator (CSM), a licensed psychologist who is board
certified in behavioral sleep medicine, will score all training
sessions. Training lasts approximately 8 weeks until the
moderators obtain mastery (scoring 100 on each session’s
Moderation Score Sheet). All moderator-provided feedback will
be delivered through email. Transcripts of moderator and
participant interactions will be stored, and 25% will be scored
by the consultant (a licensed psychologist). A senior consultant
(a licensed psychologist) will double score the initial 10 sessions
and 10 boosters and then 10% of the remaining sessions for
reliability. Consultants will inform the principal investigator
(CSM) of scores <95% for supervisory and training purposes.
The principal investigator (CSM) will review 25% and the
moderators will review 25% of each other’s sessions for ongoing
training and supervision. Only consultant reviews will be used
to assess fidelity.
Step 2: Treatment Receipt
Each week, participants will be emailed a link to their assigned
session. Automatic prompts and moderator emails will be used
to encourage session completion. To ensure treatment

https://www.researchprotocols.org/2022/6/e37874
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comprehension, participants will be encouraged to ask questions
using the embedded communication portal. Moderators will
monitor and respond within 24 hours to messages sent through
the system. Web-based materials will describe and reinforce
treatment content. Time spent viewing web-based sessions will
be monitored and recorded. Participants will complete a brief
web-based quiz at the end of session 2.
Step 3: Treatment Enactment
To ensure that assignments are completed (eg, relaxation session
completed and instructions followed), web-based materials
contain simple written instructions. Participants will maintain
daily electronic diaries and logs. Participants will complete a
patient satisfaction and experience survey at the posttreatment
and follow-up assessments. Reasons for withdrawal will be
assessed using a withdrawal questionnaire.

Treatment Credibility and Expectancy
At the end of session 2, participants will complete a treatment
credibility questionnaire. The treatment credibility questionnaire
is a 4-item scale that assesses the participant’s reaction to
therapist and treatment efficacy, and participants provide ratings
of 1 (strongly disagree) to 10 (strongly agree). Higher scores
represent better treatment credibility.

Outcomes
A summary of study outcome measures is provided in Table 1
and schedules of outcome and process measures are provided
in Tables 2 and 3.
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Table 1. Outcome measures.
Outcome category and measure

Details

Aim 1: feasibility and acceptability
Completion and adherence
Percentage of sessions completed

Percentage of sessions completed

Five instructions followed on logs

Percentage of instructions followed as indicated on treatment adherence logs

Utility and treatment satisfaction
Internet Intervention
Utility Questionnaire [38]

Satisfaction Survey

This is a 16-item measure designed to assess usability, likeability, usefulness, understandability, and convenience of an internet intervention using a 5-point Likert scale,
ranging from 0 (not at all) to 4 (very); 2 additional open-ended questions ask about
the most and least helpful aspects of the program.
This is a 9-item measure designed to provide feedback on the study, including its
structure, assessments, scheduling, working with study staff, and the usability of the
intervention platforms using a 10-point Likert scale, ranging from 1 (strongly disagree)
to 10 (strongly agree), and open-ended questions.

Aim 2: primary and mechanistic caregiver outcomes
Sleep
Daily sleep diaries

Daily electronic diaries assess caregiver sleep onset latency (lights out until sleep onset),
wake after sleep onset, and sleep efficiency (total sleep time/time in bed × 100%).

Insomnia Severity Index [39]

This is a 7-item measure designed to assess the nature, severity, and impact of insomnia
using a 5-point Likert scale, ranging from 0 (no problem) to 4 (very severe problem).

Arousal
Peripheral arousal: HRVa

HRV will be assessed using a Holter monitor during an established stress reactivity
protocol. Participants will be seated at rest and undergo Holter monitoring procedures:
(1) 5 minutes, baseline; (2) 30 seconds, vibrotactile stimuli (Conair WM200X) at 80
Hz oscillations applied to left hand; (3) 3 minutes, recovery; (4) 30 seconds, vibrotactile
stimuli applied to right hand; (5) 3 minutes, recovery; (6) cold pressor stimulation to
right hand (place hand at bottom of bowl of ice water calibrated to 4 °C); (7) 3 minutes,
recovery; and (8) cold pressor stimulation to left hand. Time and spectral analysis of
short-term HRV during baseline, vibration, and cold pressor stimuli will be conducted
using Pathfinder software (Spacelabs Healthcare). Time (reflects beat-to-beat variability: RMSSD,b pNN50c) and frequency (reflects underlying HRd rhythms: high, 0.150.4 Hz; low, 0.04-0.15 Hz; very low, <0.04 Hz, and LFe:HFf ratio] domains will be
examined. Vibration and cold pressor hand placement order will be counterbalanced
every 10 participants to account for order effects.

Chronic stress: hair cortisol

With permission, research staff will cut hair strands as close as possible to scalp
(forearm if needed [40]; minimum 50 mg of hair per sample).

Perceived Stress Scale [41]

This is a 10-item measure designed to assess past-month stress levels in response to
everyday situations using a 4-point Likert scale ranging from 0 (never) to 4 (very often).

Kingston Caregiver Stress Scale [42]

This is a 10-item measure designed to assess three categories—caregiving, family,
and financial issues—using a 5-point Likert scale ranging from 1 (feeling fine or no
stress) to 5 (extreme stress).

Dysfunctional Beliefs and Attitudes about Sleep [43] This is a 30-item measure designed to assess dysfunctional beliefs and attitudes about
sleep using a 10-point Likert scale ranging from 0 (strongly disagree) to 10 (strongly
agree).
Aim 3: secondary health-related caregiver outcomes
Health and mood
SF-36g [44]

This is a 36-item measure designed to assess quality of life using a 5-point Likert scale
ranging from 1 (poor) to 5 (excellent).

Beck Depression Inventory [45]

This is a 21-item measure designed to assess depressive symptomatology using a 4point Likert scale ranging from 0 (absence of symptoms) to 3 (severe).

State-Trait Anxiety Inventory [46]

This is a 20-item measure designed to assess anxiety using a 4-point Likert scale
ranging from 1 (not at all) to 4 (very much so).

Burden

https://www.researchprotocols.org/2022/6/e37874

XSL• FO
RenderX

JMIR Res Protoc 2022 | vol. 11 | iss. 6 | e37874 | p. 8
(page number not for citation purposes)

JMIR RESEARCH PROTOCOLS
Outcome category and measure
Zarit Burden Scale [47]
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Details
This is a 22-item measure designed to assess burden using a 5-point Likert scale
ranging from 0 (never) to 4 (nearly always).

Quality of life of caregiver of patient with dementia This is a 20-item measure designed to assess how caregiver quality of life changes
[48]
after beginning caregiving using yes or no questions and a 10-point sliding scale
ranging from 0 (easy) to 10 (hard).
Cognition
Daily Joggle battery [49]

Web-based battery designed to assess daily cognitive performance in multiple domains,
including processing speed and attention (psychomotor vigilance and digit symbol
substitution tasks), visuospatial ability and memory (visual object learning and line
orientation tasks), verbal learning and memory (auditory verbal learning task), and
executive functioning and working memory (abstract matching and n-back tasks).

NIH Toolbox for Assessment of Neurological and
Behavioral Function [50]

Computerized measure designed to assess cognitive performance in multiple domains,
including processing speed and attention (pattern comparison task), visuospatial ability and memory (picture sequence learning task), verbal learning and memory (auditory
verbal learning task), and executive functioning and working memory (dimensional
card sort and a flanker inhibition tasks).

Cognitive Failures Questionnaire [51]

This is a 25-item measure designed to assess an individual’s perception of their own
daily cognitive failures (eg, absentmindedness and memory errors) using a 5-point
Likert scale ranging from 0 (never) to 4 (very often).

Inflammation
Blood-based biomarkers

High-sensitivity CRPh and IL-6i. Plasma proteins are digested with trypsin, and peptides
specific for CRP and IL6 are quantified using multiple reaction monitoring mass
spectrometry.

Neurodegeneration
Blood-based biomarkers

Aβj40/42, tau, p-tauk-181, and p-tau-217. Plasma is extracted (Aβ40/42), or plasma
proteins are digested with trypsin, and peptides are quantified using multiple reaction
monitoring mass spectrometry.

Aim 4: persons with dementia: secondary outcome (sleep change in persons with dementia)
Actigraphy

Actiwatch 2 (Philips Respironics) is a watch-like device that will be worn 24/7 during
each 1-week assessment to monitor light and gross motor activity. Data will be analyzed
using 30-second epochs and a validated algorithm (Actiware-Sleep version 3.3; Mini
Mitter Co, Inc) to estimate total wake time.

Exploratory aim: moderators
Demographics
Demographics

Socioeconomic status, race and ethnicity, education level, marital status, financial
strain, residence, menopause symptoms, medications, comorbidities, distance (miles)
to the nearest provider, and rurality (Rurality Index [52]).

Interpersonal
Patient-Caregiver Functional Unit Scale [53]

This is a 43-item measure designed to assess how much assistance the person with
dementia needs and caregiver feelings about helping using yes or no questions and 2
types of Likert scales: a 3-point scale ranging from 0 (without help) to 2 (completely
unable) and a 4-point scale ranging from 0 (no) to 3 (both physically and emotionally
difficult).

Shared lifestyle
Godin-Shephard Leisure-Time Physical Activity
Questionnaire [54]

This is a 3-item measure designed to assess how many times per week an individual
engages in mild, moderate, or strenuous activity and asks the number of times per
week the items were accomplished.

Fruit and vegetable servings

Amount of fruit and vegetable servings per day

Respite and assistance
Respite

Amount and type of respite

Assistance

Assistance provided by secondary informal caregivers (number, relationship, hours:
face-to-face vs other).

Dementia severity of persons with dementia
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Outcome category and measure

Details

Dementia Severity Rating Scale [55]

This is an 11-item measure designed to assess severity of functional and cognitive
decline in patients with Alzheimer disease using various Likert scales.

Nighttime behaviors of persons with dementia
Neuropsychology Inventory Nighttime Behavior
Scale [56]
a

This is an 8-item measure designed to assess frequency and severity of detrimental
sleep behaviors, such as wandering, in the dementia patient using yes or no questions.

HRV: heart rate variability.

b

RMSSD: root mean square of successive RR interval differences. RR interval is the time between 2 detected heartbeats, calculated for every QRS
event.
c

pNN50: The proportion of NN50 divided by the total number of NN (R-R) intervals. NN50 is the number of times successive heartbeat intervals exceed
50 ms. RR interval is the time between 2 detected heartbeats, calculated for every QRS event. NN interval is the time (normalized) between 2 detected
heartbeats, calculated for every QRS event.
d

HR: heart rate.

e

LF: low frequency.

f

HF: high frequency.

g

SF-36: Short Form-36 Health Survey Questionnaire.

h

CRP: C-reactive protein.

i

IL-6: interleukin-6.

j

Aβ: plasma amyloid beta.

k

p-tau: phosphorylated tau.

Table 2. Schedule of outcome measures.
Baseline

Treatment

After treatment

Boosters

6-month 12-month
follow-up follow-up

Assessment period, weeks

1

4

1

1

1

1

Screening, apnea testing, consent and assent, and demographics

✓
✓

✓

✓

✓

✓

HRV,a ISI,b PSS,c KCGSS,d inflammation and neurodegeneration
e

f

g

h

✓

i

biomarkers, cortisol, actigraphy, SF-36, BDI, STAI, DBS, ZBS,

QoL,j daily Joggle battery, NIH Toolbox for Assessment of Neurological and Behavioral Function, CFQ,k P-CG FUS,l G-S L-T PAQ,m
fruit and vegetable servings per day, respite, secondary CGn outcomes,
DSRS,o NPI,p and NBSq
Electronic daily diaries
a

✓

✓

✓

✓

HRV: heart rate variability.

b

ISI: Insomnia Severity Index.

c

PSS: Perceived Stress Scale.

d

KCGSS: Kingston Caregiver Stress Scale.

e

SF-36: Short Form-36 Health Survey Questionnaire.

f

BDI: Beck Depression Inventory.

g

STAI: State-Trait Anxiety Inventory.

h

DBS: Dysfunctional Beliefs about Sleep.

i

ZBS: Zarit Burden Scale.

j

QoL: Quality of life of caregiver of patient with dementia.

k

CFQ: Cognitive Failures Questionnaire.

l

P-CG FUS: Patient-Caregiver Functional Unit Scale.

m

G-S L-T PAQ: Godin-Shephard Leisure-Time Physical Activity Questionnaire.

n

CG: caregiver.

o

DSRS: Dementia Severity Rating Scale.

p

NPI: Neuropsychological Inventory.

q

NBS: Nighttime Behavior Scale.
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Table 3. Schedule of process measures.

Assessment period (weeks)

Baseline

Treatment

After treatment

Boosters

6-month
follow-up

12-month
follow-up

1

4

1

1

1

1

✓

✓

✓

✓

Treatment integrity: delivery and receipt and enactment

✓

✓

Treatment credibility: quiz and improvement expectancy

✓

✓

Sleep knowledge and working alliance

✓

✓

✓

Study Timeline
The study timeline is provided in Table 4.
Table 4. Study timeline.
Project year
1
First
half

2

3

4

5

Second
half

First
half

Second
half

First
half

Second
half

First
half

Second
half

First
half

Second
half

Recruit, collect baseline measurements, and deliver treatment

✓

✓

✓

✓

✓

✓

Collect assessment after treatment

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

Develop manual of operating procedures, register with
✓
ClinicalTrials.gov, publish trial protocol, and train moderators and assessors

Collect 6- and 12-month follow-up assessments
Offer and provide NiteCAPP CARESa to NiteCAPP
b

SHARES participants
Final data analysis and dissemination (continues after grant
ends) and final report
a

NiteCAPP CARES: cognitive behavioral therapy for insomnia.

b

NiteCAPP SHARES: active web-based sleep hygiene and related education control.

Analytical Approach
Power Analysis
Power will be simulated using SAS 9.4 statistical software (SAS
Institute Inc) using a generalized estimating equations (GEE)
design (clusters are individuals measured over 4 time points)
with an autoregressive working correlation structure (correlation
decreases as time point distance increases, ρ=0.5, 1 million
Monte Carlo integrations simulated) [57]. The approach
described by Schluchter [58] will fit GEE models with and
without mediator to estimate mediated effect (exploratory aim).
Sample size of 80 is powered (>.80) to detect small to large
Cohen d mediation effects. Given an anticipated dropout rate
of 15% to 20%, we will recruit a total sample of 120.

Evaluations of Aims
Tests of Hypotheses
All analyses will use intent-to-treat using all randomized
participants. All assumptions will be tested. If the normality
assumption is violated, the nonparametric Mann-Whitney U
test will be used.
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Testing of Aim 1: Feasibility and Acceptability of NiteCAPP
CARES and NiteCAPP SHARES
The feasibility and acceptability of NiteCAPP CARES and
NiteCAPP SHARES will be evaluated using average completion
rates (number of sessions completed), adherence (measured
through sleep diaries and logs), and satisfaction and utility
ratings. These variables will be compared for NiteCAPP CARES
and NiteCAPP SHARES using independent samples 2-tailed t
tests.
Testing of Aims 2 to 4: Primary and Mechanistic and
Secondary Outcomes
A mediated GEE model [58] (clusters are individuals measured
over 4 time points) will test causal paths between intervention
effects on the primary and secondary outcomes (Figure 3). On
the basis of a priori hypotheses, separate GEE models, including
group (NiteCAPP CARES and NiteCAPP SHARES), time
(baseline, after treatment, and 6-month and 12-month
follow-ups), and their interaction as predictors, will be
conducted for each primary CG outcome (aim 2: insomnia
severity, sleep onset latency, wake after sleep onset, sleep
efficiency, arousal, and inflammation), secondary CG outcome
(aim 3: health, mood, burden, and cognitive performance), and
secondary outcome for persons with dementia (aim 4: actigraphy
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total wake time for persons with dementia). Potential covariates
affecting the mechanistic outcomes (Table 2) or technology use
by CGs and persons with dementia (eg, Internet Intervention
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Utility Questionnaire [38]) will be assessed and used as
covariates if significant.

Figure 3. Mediated generalized estimating equations model. Analyses will also be conducted examining the paths from after treatment to 6-month
follow-up and from 6-month follow-up to 12-month follow-up. Base: baseline; CG: caregiver; F6: 6-month follow-up; F12: 12-month follow-up;
NiteCAPP CARES: cognitive behavioral therapy for insomnia; NiteCAPP SHARES: active web-based sleep hygiene and related education control;
Post: after treatment.

Testing of Exploratory Aim
We will evaluate primary and secondary outcome change
relationships and their potential mediators and moderators (Table
2). Mediated GEE will be used to compare NiteCAPP CARES
versus NiteCAPP SHARES. Moderating effects will be tested
using interactions (Table 2).

Missing Values
The SAS PROC GEE weighted model handles missing data
completely at random or at random. When measures are
collected over time, some participants may not complete the
study. Unlike repeated measures ANOVA, which excludes them
from analysis, weighted GEE retains them (increasing power
and producing unbiased estimates).

Patient and Public Involvement
Patients and the public are not involved in any of the following
study procedures: development of research questions and
outcome measures or plan for results dissemination. The
Community Advisory Board (CAB) will assess the burden of
the intervention and may help with recruitment. Every
participant will fill out a patient satisfaction and experience
survey after treatment and at 6-month and 12-month follow-ups.
This questionnaire asks CGs and persons with dementia which
modules were most and least useful for them, how they felt
about the length of the program, suitability for CGs and persons
with dementia, and so on. Trial results will be communicated
to participants and the public through peer-reviewed
manuscripts.

Ethics Approval
All procedures were approved by the University of Missouri
Institutional Review Board on May 6, 2021 (2053682); safety
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officer Dr Susan McCurry on November 24, 2021; the National
Institute of Aging (NIA) on January 26, 2022; and the University
of South Florida Institutional Review Board on March 10, 2022
(003936). The NIA and the safety officer reviewed and approved
the study protocol, manual of operating procedures, informed
consent form, and monitoring plan with emphasis on data
integrity and patient safety issues in November 2021. The safety
officer will review these biannually. Any changes to these
procedures that are recommended by the safety officer will be
adopted with institutional review board and NIA approval. The
safety officer will review adverse events and monitor study
results, focusing on efficacy, recruitment progress,
randomization, compliance, retention, protocol adherence,
operating procedures, forms completion, intervention effects,
participant safety, and minority inclusion. The principal
investigator (CSM) registered the study with ClinicalTrials.gov
(NCT04896775) on May 21, 2021, and will submit annual
reports to the funding agency.
Our team includes a CAB comprising 8 CGs, 4 persons with
dementia, and 4 local experts. The CAB structure and procedures
are based on the CAB Toolkit described by Kubicek and Robles
[59]. The CAB will meet twice each year, with each meeting
lasting 2 hours (respite care costs for persons with dementia
will be paid by the grant). The team includes a consultant CG
advocate who is a trained facilitator, and she will facilitate the
CAB meetings.

Results
This work is supported by the National Institutes of Health’s
NIA (R01AG066081). Recruitment procedures started in
February 2022. All data are expected to be collected by 2026.
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Full trial results are planned to be published by 2027. Secondary
analyses of baseline data will be subsequently published.
We will present the findings at national conferences, including
the Associated Professional Sleep Societies (APSS or SLEEP)
and the Gerontological Society of America, in the final year of
the project. An abstract reporting the findings of the preproposal
focus group was presented at the August 2020 internet-based
SLEEP meeting, and a brief report based on these findings is
currently under review. The web-based treatment materials will
be shared electronically and will be widely available to
clinicians. The findings will also be disseminated to the
dementia and dementia caregiving communities through
websites and other resources. The team’s community CG
advocate and CAB will be involved in planning for broad
dissemination to the dementia and CG communities. They will
also help to ensure that materials used to disseminate findings
are written for, and easily understood by, lay audiences in rural
areas.

Discussion
The overarching goal of this RCT is to evaluate the acceptability,
feasibility, and short-term and long-term effects of NiteCAPP
CARES on the sleep and stress mechanisms underlying poor
CG health and functioning. To the best of our knowledge, there
is no current web-based CBT-I treatment that is tailored for
CGs of persons with dementia and none that involve the person
with dementia in treatment.

Strengths and Limitations
This study includes several strengths. It is a novel 4-week
web-based CBT-I (NiteCAPP CARES) in CGs and persons
with dementia (using a dyadic approach) that integrates sleep

McCrae et al
education, sleep hygiene, stimulus control, sleep compression,
relaxation, problem solving, coping and stress management,
and cognitive restructuring techniques. This study uses a
rigorous methodology and NiteCAPP CARES will be examined
in comparison with an active web control (NiteCAPP SHARES).
Long-term follow-ups at 6 and 12 months will enable
examination of the persistence of the behavioral outcomes of
NiteCAPP CARES. The potential limitations include participant
attrition at follow-up, which may contribute to selection bias
associated with systematic differences between participants
completing NiteCAPP CARES and those completing NiteCAPP
SHARES.

Future Directions
Future directions for this RCT include a multisite effectiveness
trial to determine generalizability across different areas. In
addition, once NiteCAPP CARES is enhanced based on the
results of this RCT, it needs to be tested within other populations
(nonrural CGs and other underserved populations) for broader
dissemination. Finally, dismantling studies could examine the
most effective components of NiteCAPP CARES treatment to
further streamline the treatment.

Conclusions
This RCT tests NiteCAPP CARES, a web-based CBT-I for rural
CGs. The Cognitive Activation Theory of Stress and our
research as well as research conducted by others [7,31] support
our novel hypothesis that NiteCAPP CARES will improve CG
health, mood, burden, and cognition by targeting sleep, arousal,
and inflammation. This trial addresses what improves as well
as how, why, and for how long (up to 1 year). This trial is a
necessary first step, and the results from this study will help us
to modify NiteCAPP CARES to optimize treatment potency
and support future pragmatic testing and dissemination.
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